The university is running a £14m drug safety study
It intends to shed new light on bad reactions to drugs
The University is planning a new research project, costing £14 million, that intends to shed new light on bad reactions to drugs through ‘cutting-edge’ modelling approaches to drug safety.
The five-year project, called Translational Quantitative Systems Toxicology to Improve the Understanding of the Safety of Medicines (TransQST), aims to develop novel approaches using the best available data from public and private domains to address drug safety issues.
The project co-ordinator professor Kevin Park from the University’s Institute of Translational Medicine said:
“The fear of ADRs is a major impediment to the development of new, safe and effective therapies. This project will enable us to leverage the best available data and expertise from both public and private domains to generate and validate novel computational models that will help to address the problems of safe drug development”.
The project is funded by Europe’s largest public-private initiative, IMI2, striving to accelerate development of better and safer medicines for patients.